Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Product mismatch in the original source: the heading says INVOKANA but the body describes INVOKAMET. The complete original statement is preserved; do not apply its combination-product instructions to single-agent canagliflozin.
All record notes are retained here, including notes about sources not selected in this review.
Invokana - product and source limitations
Use the prescribing information's separate UGT-inducer instructions when applicable. This continuation exception does not transfer to canagliflozin/metformin.
What to reconcile: Apply only to the stated formulation, indication and renal population.
Renal guidance: 2, renal impairment and interacting drugs
For adults with eGFR 30 to <60, the usual renal maximum is 100 mg once daily. Below 30, initiation is not recommended. Adults already taking it who have albuminuria >300 mg/day may continue 100 mg daily for the labeled cardiorenal indication. Use the prescribing information's separate UGT-inducer instructions when applicable. This continuation exception does not transfer to canagliflozin/metformin.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
